AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Efficacy of Dorso-lateral Prefrontal Cortex Stimulation by tDCS in Motor Conversion Disorder Patients

RecruitingNAAges 18 Years - 65 YearsAllCentre Hospitalier Universitaire de Nīmes
💬

In plain words

What the trial is, and whether it could suit you

Conversion disorder refers to impaired voluntary motor or sensory functions that are not compatible with a well-known neurological condition. This disorder affects up to 30% of hospitalized patients in neurology departments and symptoms persist in 35% of patients after 12 years of evolution. Despite a poor prognosis, no treatments have been validated to date. The development of non-invasive brain stimulation techniques has allowed the creation of treatments focused on dysfunctional brain regions associated with motor conversion disorder. Hypoactivation of prefrontal dorso-lateral cortex underlies the course of functional motor symptoms. Results of the HYCORE study conducted at Nîmes University Hospital (including 20 patients, clinicaltrial.gov NCT02329626) confirmed these results and related hypoactivation of PFDLC to persistent motor disability at 3 months and 6 months follow-up. Activ

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * The patient must have given his/her informed and signed consent. * The patient is at least (≥) 18 years old and 65 years old at the most (≤). The risk of an increased frequency of somatic comorbidity, drug co-prescription, and cognitive impairment prompts us to limit recruitment to age 65 in this study. * The patient is hospitalized or followed in consultation. * Patient is available for a follow-up of 6 months. * With current DSM-5 criteria for conversion disorder during more than 10 days, motor type (i.e. with paralysis or motor weakness) and initial EDSS score ≥ 3 or initial WHO Score is ≥ 2 Exclusion Criteria: * The patient is participating in another interventional trial. * The patient refuses to sign the consent. * It is impossible to correctly inform the patient. * The patient is pregnant or breastfeeding. * Specialized neurological clinical examination and the performing of brain and medullary MRI reveal an organic neurological involvement. * Current episode of mania, hypomania, diagnosis of substance abuse/dependence (excluding smoking), diagnosis of schizophrenia over lifetime, severe neurological pathology (epilepsy, stroke, brain tumor). * Patient with a contraindication to MRI (for patients enrolled in Nîmes). * Acute eczema at the electrodes loci.
💊

What it tests

  • Neurostimulation with non-implanted electrodes
📍

Where

8 sites
Centre Hospitalier Universitaire
Nîmes, France
Hôpital La Colombière Service de Psychiatrie
Montpellier, France
CHU de Montpellier Hôpital Gui De Chauliac Service de Neurologie
Montpellier, France
Hôpital Lapeyronie
Montpellier, France
Hospices Civils de Lyon Hôpital Edouard Herriot
Lyon, France
CHU de Nantes
Nantes, France
Clinique St Exupery
Toulouse, France
Hôpital Saint-Antoine Service de Psychiatrie APHP
Paris, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy